Individual #00408724

ID_report ?
Reference PubMed: Spaide 2021
Remarks -
Gender F
Consanguinity -
Country -
Population English, Scottish
Age at death -
VIP -
Data_av -
Treatment -
Panel size 1
Diseases retinal disease
Owner name LOVD
Database submission license Creative Commons Attribution 4.0 InternationalCreative Commons License
Created by Anna Tracewska
Date created 2022-04-26 11:29:39 +02:00 (CEST)
Date last edited N/A


Phenotypes

retinal disease (-)   Add phenotype for this disease

AscendingPhenotype ID     

Phenotype details     

Diagnosis/Initial     

Diagnosis/Definite     

Inheritance     

Age/Examination     

Age/Diagnosis     

Age/Onset     

Phenotype/Onset     

Protein     

Owner     
0000300843 bilateral macular neovascularization - photodynamic therapy (PDT) in the right eye once, 5x in the left eye; best corrected visual acuity right, left eye: 20/25, 20/400 in the left; family history: affected mother, maternal aunt, and two maternal cousins; treatment with PDT and an intravitreal injection of triamcinolone 4 mg - dramatic reduction in the neovascularization in both eyes; signs of recurrence right eye after 9 months - retreatment; left eye: extensive scarring and received no further treatment; then, periodic intravitreal triamcinolone injections alone, switched to bevacizumab and later with ranibizumab, but with each of these she repeatedly developed signs of exudation and hemorrhage by 1 month after injection; maintained on intravitreal injections of 4 mg triamcinolone approximately every 3 -4 months; corticosteroid-related cataract extraction and filtering surgery for uncontrolled glaucoma; optical coherence tomography: extensive double-layered sign with - a large area of neovascularization; due to the perceived increased risk for endophthalmitis in an eye with a filtering bleb receiving intraocular corticosteroid injections, an effort was made to switch the patient to a therapy with a lower endophthalmitis risk - a TNFalpha inhibitor, adalimumab, 2 40 mg doses subcutaneously followed by 40 mg every twice monthly - complete cessation of disease activity - Sorsby fundus dystrophy Familial, autosomal dominant 35y - - - - LOVD



Screenings


AscendingScreening ID     

Template     

Technique     

Tissue     

Remarks     

Genes screened     

Variants found     

Owner     
0000409988 DNA ? - - TIMP3 1 LOVD



Variants

1 entry on 1 page. Showing entry 1.
Legend   How to query  

Chr     

Allele     

Effect     

Classification method     

Clinical classification     

AscendingDNA change (genomic) (hg19)     

DNA change (hg38)     

Published as     

ISCN     

DB-ID     

Variant remarks     

Reference     

ClinVar ID     

dbSNP ID     

Origin     

Segregation     

Frequency     

Re-site     

VIP     

Methylation     

Owner     

Gene     

IDbase Accession Number     

VariO/DNA     

VariO/Protein     

VariO/RNA     

Exon     

DNA change (cDNA)     

Haplotype     

RNA change     

Protein     

P-domain     

Exon_old     

Function/GVS     

Predict/AGVGD     

Predict/MutationTaster     

Predict/SIFT     

Predicted     

Type/DNA     

CpG     

Enzyme activity     

mRNA level     

Predict-BioInf     

Legacy protein change     

Protein level     
22 Maternal (inferred) +?/. - likely pathogenic g.33255338A>T g.32859351A>T TIMP3 610A>T; p.(Ser204Cys) - SYN3_000016 - PubMed: Spaide 2021 - - Germline yes - - - - LOVD SYN3, TIMP3 - - - - - NM_001135774.1:c.708+5564T>A, NM_000362.4:c.610A>T - r.(=), r.(?) p.(=), p.(Ser204Cys) - - - - - - - - - - - - - -
Legend   How to query  


Screenscraping/webscraping (downloading large amounts of data using scripts) is strictly prohibited.
Use our APIs to retrieve data.